CoChat

Efficacy and safety of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24‐week, randomized, double‐blind, placebo‐controlled trial

Open access
Kadowaki, Takashi, Inagaki, Nobuya, Kondo, Kazuoki, Nishimura, Kenichi, Kaneko, Genki, Maruyama, Nobuko, Nakanishi, Nobuhiro, Iijima, Hiroaki, Watanabe, Yumi, Gouda, Maki · 2017 · Diabetes, Obesity and Metabolism
Cited by 57

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Aims: To investigate efficacy and safety of the sodium–glucose co‐transporter 2 ( SGLT2 ) inhibitor canagliflozin administered as add‐on therapy to the dipeptidyl peptidase‐4 ( DPP ‐4) inhibitor teneligliptin in patients with type 2 diabetes mellitus ( T2DM ). Materials and methods: We conducted a multicentre, randomized, double‐blind, placebo‐controlled, phase 3 clinical trial in J apanese patients with T2DM who had inadequate glycaemic control with teneligliptin. Patients were randomized to receive teneligliptin 20 mg plus either canagliflozin 100 mg ( T + C , n = 70) or placebo ( T + P , n = 68) once daily. The primary endpoint was the change in glycated haemoglobin ( HbA1c ) from baseline to week 24. Other endpoints included changes in fasting plasma glucose, body weight, proinsulin/ C ‐peptide ratio, homeostatic model assessment 2‐% B and adverse events. Patients also underwent mixed‐meal tolerance tests. Results: The difference between the T + C and T + P groups for HbA1c change from baseline to week 24 was −0.88% (least‐squares mean, P < .001). Fasting plasma glucose, body weight and the proinsulin/ C ‐peptide ratio were significantly lower in the T + C group than in the T + P group. Homeostatic model assessment 2‐% B improved with T + C compared with T + P . The T + C group exhibited a decrease in the 2‐hour postprandial plasma glucose and plasma glucose area under the curve ( AUC ) 0‐2h in a mixed‐meal tolerance test. No significant between‐group differences were observed for C ‐peptide AUC 0 ‐2h or glucagon AUC 0 ‐2h after meals. Incidences of adverse events were 60.0% and 47.1% in the T + C and T + P groups, respectively. No hypoglycaemia was observed. Conclusions: Canagliflozin administered as add‐on therapy to teneligliptin was effective and well tolerated in J apanese T2DM patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12898

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

Metadata

Authors
Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G., Maruyama, N., Nakanishi, N., Iijima, H., Watanabe, Y., & Gouda, M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2017-03-31
Volume
19
Issue
6
Pages
874-882
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2586681261
Cited by
57
References
3
FWCI
5.94
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.